{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:22:18Z","timestamp":1794540138814,"version":"4.9.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Primary leptomeningeal melanoma is an extremely rare disease of the central nervous system. There are no standard treatment protocols with a poor prognosis in very few reported cases. Immunotherapy in primary brain melanoma has not been successfully applied so far.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We describe a female patient 72-year-old diagnosed in the Neurosurgery Department which presented with generalized seizures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Histological examination confirmed atypical melanocytes immunohistochemically positive for melan A, HMB45 and S-100 protein in the meninges, BRAF V600E negative. Dermatological, ophthalmological examinations, and 18-FDG PET\/CT were negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was successfully treated with pembrolizumab 2\u200amg\/kg every 3 weeks for 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The disease was stable for 2 years and the patient had no significant toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Our report describes durable intracranial tumor response suggesting the efficacy of PD-1 inhibitor pembrolizumab for central nervous system primary leptomeningeal melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000022928","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T16:57:50Z","timestamp":1607619470000},"page":"e22928","source":"Crossref","is-referenced-by-count":13,"title":["Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-7104","authenticated-orcid":false,"given":"Ana","family":"Misir Krpan","sequence":"first","affiliation":[{"name":"University Hospital Centre Zagreb, Kispaticeva 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Rakusic","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, Kispaticeva 12"},{"name":"University of Zagreb, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorin","family":"Herceg","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, Kispaticeva 12"},{"name":"University of Zagreb, School of Dental Medicine, Zagreb, Croatia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2018.01.052","article-title":"Primary diffuse leptomeningeal melanomatosis: description and recommendations","volume":"50","author":"Saadeh","year":"2018","journal-title":"J Clin Neurosci"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1215\/15228517-2008-062","article-title":"Prognostic factors and outcomes in patients with leptomeningeal melanomatosis","volume":"10","author":"Harstad","year":"2008","journal-title":"Neuro-Oncol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10143-017-0914-0","article-title":"Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature","volume":"41","author":"Fujimori","year":"2018","journal-title":"Neurosurg Rev"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"1727116","DOI":"10.1080\/2162402X.2020.1727116","article-title":"Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors","volume":"9","author":"Simon","year":"2020","journal-title":"Oncoimmunology"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"948497","DOI":"10.1155\/2015\/948497","article-title":"Meningeal melanomatosis: a challenge for timely diagnosis","volume":"2015","author":"Berzero","year":"2015","journal-title":"Biomed Res Int"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-18-0763","article-title":"Integrated genomic classification of melanocytic tumors of the central nervous system using mutation analysis, copy number alterations, and DNA methylation profiling","volume":"24","author":"Griewank","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R8-20230916","first-page":"e4446","article-title":"Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier","volume":"11","author":"Abid","year":"2019","journal-title":"Cureus"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-018-2848-y","article-title":"Pembrolizumab for primary malignant melanoma of the central nervous system","volume":"139","author":"El Habnouni","year":"2018","journal-title":"J Neurooncol"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/annonc\/mdz083","article-title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","volume":"30","author":"Bartels","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:10:09Z","timestamp":1694812209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022928"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":11,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022928","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}